Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial-Reference-Cited by-同舟云学术

Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

Published:2005-12-06 Issue:2 Volume:58 Page:203-209
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Dongiovanni Vincenzo,Buffoni Lucio,Berruti Alfredo,Dongiovanni Diego,Grillo Raffaella,Barone Carla,Addeo Alfredo,Fissore Camilla,Bertetto Oscar

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-005-0157-6.pdf

Reference35 articles.

1. Ihde DC (1995) Small cell lung cancer state-of-the-art therapy 1994. Chest 107:243S–248S

2. Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR (1979) The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44:406–413

3. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83(12):855–861

4. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, NC Cherng LP, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO (1992) Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer:a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282–291

5. Sundstrøm SM, Bremnes R, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III with 5 years’ follow-up. J Clin Oncol 20:4665–4672

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous LC-MS/MS bioanalysis of etoposide and paclitaxel in mouse tissues and plasma after oral administration of self-microemulsifying drug-delivery systems;Biomedical Chromatography;2018-02-22

2. Differenzialtherapie des fortgeschrittenen metastasierten kleinzelligen Lungenkarzinoms;Der Onkologe;2017-04-04

3. Prise en charge thérapeutique des tumeurs neuroendocrines peu différenciées pulmonaires et des carcinomes neuroendocrines digestifs;Bulletin du Cancer;2016-10

4. A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer;Cancer Research and Treatment;2016-04-15

5. Poorly Differentiated Neuroendocrine Tumors;Hematology/Oncology Clinics of North America;2016-02